ARA‑290 — Technical Product Information
1. Product Overview
ARA‑290 is a synthetic peptide derived from the EPO (erythropoietin) molecule, specifically the helix B surface peptide (HBSP), which is responsible for tissue-protective signaling but not erythropoiesis. It is being investigated for its tissue-protective, anti-inflammatory, and regenerative properties.
-
Chemical Name: Helix B Surface Peptide (HBSP) derivative
-
Peptide Sequence: Typically 11 amino acids (specific sequence: SQVTLSLSF) — may vary slightly depending on synthesis protocol
-
Molecular Weight: ~1.2 kDa (approximate)
-
Formulation: Lyophilized powder
-
Intended Use: Research use only (RUO); under clinical investigation for tissue protection in conditions like neuropathy, ischemia, and inflammatory diseases.
2. Physical & Chemical Specifications
| Property | Specification |
|---|---|
| Peptide Content | Typically 1–10 mg per vial (depends on supplier) |
| Form | White to off-white lyophilized powder |
| Purity | ≥ 98 % (HPLC verified) |
| Solubility | Soluble in sterile water, saline, or buffer solutions |
| Molecular Weight | ~1.2 kDa |
| Storage (Lyophilized) | –20 °C, protect from light and moisture |
| Storage (Reconstituted) | 2–8 °C; avoid repeated freeze–thaw cycles |
3. Mechanism of Action (Research Context)
ARA‑290 selectively activates the tissue-protective erythropoietin receptor (EPOR/βcR heteromer) without stimulating the classical erythropoietic receptor, providing:
-
Anti-inflammatory effects: Downregulates pro-inflammatory cytokines such as TNF-α and IL-6
-
Tissue protection: Protects cells from apoptosis under stress conditions like ischemia or injury
-
Neuroprotection: Promotes regeneration and repair in neuropathic tissues
-
Wound healing and vascular protection: Stimulates endothelial cell survival and angiogenesis in experimental models
Mechanistic evidence comes from preclinical and early-phase clinical studies; not an approved drug.
4. Composition & Peptide Characteristics
-
Short, linear synthetic peptide (11 amino acids) derived from EPO helix B
-
High solubility and stability for laboratory and clinical research
-
Not immunogenic at experimental concentrations in vitro and in vivo models
5. Reconstitution & Handling Guidelines
Reconstitution:
-
Reconstitute in sterile water or 0.9 % saline according to desired concentration.
-
Gently swirl; avoid vigorous shaking.
-
Store reconstituted solution at 2–8 °C; typically stable for 24–48 h in solution.
Handling:
-
Laboratory research use only
-
Use standard peptide-handling protocols (PPE, sterile technique)
-
Dispose of unused solutions per institutional safety guidelines
6. Research Applications
ARA‑290 is primarily studied for:
-
Peripheral neuropathy (including small fiber neuropathy)
-
Ischemic injury protection (heart, kidney, and neural tissue)
-
Anti-inflammatory and tissue-regenerative research
-
Clinical translational research exploring non-erythropoietic EPO analogs
7. Safety & Regulatory Notes
-
For research use only (RUO)
-
Not approved as a therapeutic, supplement, or diagnostic agent
- Follow institutional safety and handling guidelines for synthetic peptides
Reviews
There are no reviews yet.